https://okyopharma.com/notification-of-major-holdings/ 2018-08-22T19:33:00+00:00 https://okyopharma.com/result-of-agm/ 2018-09-06T19:31:00+00:00 https://okyopharma.com/okyo-pharma-sees-big-opportunities-for-its-dry-eye-and-pain-management-technology/ 2018-09-12T11:00:00+00:00 https://okyopharma.com/allotment-of-ordinary-shares-and-listing-application/ 2018-10-24T19:29:00+00:00 https://okyopharma.com/expected-admission-date-for-consideration-shares/ 2018-11-01T20:27:00+00:00 https://okyopharma.com/interim-results-for-the-six-months-to-30-september-2018/ 2018-11-30T20:25:00+00:00 https://okyopharma.com/okyo-pharma-corporate-update/ 2019-01-23T07:00:00+00:00 https://okyopharma.com/presentation-of-preclinical-data-demonstrating-potential-of-okyo-0101-for-dry-eye-treatment/ 2019-03-07T07:00:00+00:00 https://okyopharma.com/okyo-releases-preclinical-data-on-okyo-0101-at-the-14th-congress-on-ocular-pharmacology-and-therapeutics-2019-demonstrating-its-potential-to-treat-dry-eye/ 2019-03-14T10:00:00+00:00 https://okyopharma.com/subscription-of-36363636-new-ordinary-shares-at-a-price-of-1-1-pence-per-share-to-raise-gross-proceeds-of-gbp-400000-proposed-approval-of-waiver-of-the-obligations-under-rule-9-of-the-takeover-code-an/ 2019-04-26T05:05:00+00:00 https://okyopharma.com/result-of-general-meeting-admission-of-subscription-shares-and-total-voting-rights/ 2019-05-20T09:56:00+00:00 https://okyopharma.com/tr-1-notification-of-major-holdings/ 2019-05-30T13:41:00+00:00 https://okyopharma.com/final-audited-results-for-the-year-ended-31-march-2019/ 2019-07-01T06:45:00+00:00 https://okyopharma.com/okyo-pharma-announces-collaboration-with-prof-pedram-hamrah-to-evaluate-proprietary-lead-compounds-as-non-opioid-analgesics-targeting-g-protein-coupled-receptors/ 2019-08-19T05:05:00+00:00 https://okyopharma.com/okyo-pharma-announces-potent-anti-inflammatory-effects-of-ok-113-a-novel-agonist-of-chemerin-g-protein-coupled-receptor-in-a-mouse-model-of-dry-eye-disease/ 2019-08-28T05:05:00+00:00 https://okyopharma.com/interim-results-for-the-six-months-to-30-september-2019/ 2019-11-29T07:10:00+00:00 https://okyopharma.com/directorate-change-4/ 2019-12-19T07:02:00+00:00 https://okyopharma.com/result-of-annual-general-meeting-2/ 2020-03-02T12:00:00+00:00 https://okyopharma.com/placing-to-raise-gbp-560000/ 2020-03-19T07:02:00+00:00 https://okyopharma.com/update-on-placing-to-raise-gbp-560000/ 2020-03-23T07:02:00+00:00 https://okyopharma.com/tr-1-standard-form-for-notification-of-major-holdings-5/ 2020-03-30T05:18:00+00:00 https://okyopharma.com/tr-1-standard-form-for-notification-of-major-holdings-4/ 2020-04-27T09:13:00+00:00 https://okyopharma.com/tr-1-standard-form-for-notification-of-major-holdings-3/ 2020-05-27T13:21:00+00:00 https://okyopharma.com/balance-of-placing-to-raise-gbp-560000-announced-on-23-march-2020/ 2020-05-28T17:16:00+00:00 https://okyopharma.com/issue-of-convertible-loan-notes-to-raise-gbp-440000/ 2020-05-29T16:30:00+00:00 https://okyopharma.com/appointment-of-broker/ 2020-06-03T09:13:00+00:00 https://okyopharma.com/tr-1-standard-form-for-notification-of-major-holdings-2/ 2020-06-05T09:20:00+00:00 https://okyopharma.com/directorate-change-3/ 2020-06-10T15:23:00+00:00 https://okyopharma.com/issue-of-convertible-loan-notes-to-raise-gbp-3500000/ 2020-07-28T06:54:00+00:00 https://okyopharma.com/upcoming-presentation/ 2020-07-31T14:31:00+00:00 https://okyopharma.com/company-presentation/ 2020-08-03T05:02:00+00:00 https://okyopharma.com/holdings-in-company/ 2020-08-06T05:03:00+00:00 https://okyopharma.com/dr-james-khodabakhsh-md-named-chairman-of-the-sab/ 2020-08-07T05:02:00+00:00 https://okyopharma.com/final-audited-results-for-the-year-ended-31-march-2020/ 2020-08-17T15:01:00+00:00 https://okyopharma.com/issue-of-additional-convertible-loan-notes-to-raise-gbp-1437104-and-intention-to-seek-dual-listing-on-nasdaq/ 2020-08-18T05:02:00+00:00 https://okyopharma.com/appointment-of-dr-napoleone-ferrara-to-serve-on-its-scientific-advisory-board/ 2020-08-19T07:03:00+00:00 https://okyopharma.com/grant-of-options-director-dealings-2/ 2020-08-21T05:02:00+00:00 https://okyopharma.com/issue-of-convertible-loan-notes-to-raise-an-additional-gbp-500000/ 2020-09-08T07:21:00+00:00 https://okyopharma.com/notice-of-annual-general-meeting-2/ 2020-09-09T05:01:00+00:00 https://okyopharma.com/upload-of-articles-of-association-to-national-storage-mechanism/ 2020-09-25T10:02:00+00:00 https://okyopharma.com/result-of-the-annual-general-meeting/ 2020-09-25T10:02:00+00:00 https://okyopharma.com/interim-results-for-the-six-months-to-30-september-2020/ 2020-11-30T07:02:00+00:00 https://okyopharma.com/directorate-changes-and-pdmr-dealing/ 2021-01-07T07:02:00+00:00 https://okyopharma.com/okyo-announces-filing-of-a-patent-application-covering-the-use-of-chemerin-and-associated-analogues-to-treat-cytokine-storm-associated-with-covid-19-and-ards/ 2021-01-19T07:00:00+00:00 https://okyopharma.com/okyo-pharma-has-us-patent-issued-covering-its-lipid-conjugated-peptide-analogues-for-treating-ocular-pain-and-inflammation/ 2021-02-23T07:02:00+00:00 https://okyopharma.com/issue-of-equity/ 2021-03-01T07:01:00+00:00 https://okyopharma.com/issue-of-equity-update/ 2021-03-03T07:01:00+00:00 https://okyopharma.com/okyo-pharma-limited-ceo-gary-jacob-tells-proactives-andrew-scott-its-time-to-take-the-company-from-development-stage-and-into-the-clinic/ 2021-03-10T16:00:00+00:00 https://okyopharma.com/okyo-announces-appointment-of-dr-rajkumar-patil-as-chief-scientific-officer/ 2021-03-29T05:02:00+00:00 https://okyopharma.com/okyo-pharma-announces-positive-data-and-results-in-an-animal-model-using-topically-administered-ok-201-to-treat-neuropathic-ocular-pain/ 2021-04-28T05:01:00+00:00 https://okyopharma.com/prospectus-publication-announcement/ 2021-05-05T09:58:00+00:00 https://okyopharma.com/admission-of-additional-shares-to-listing-on-the-official-list-and-to-trading-on-the-london-stock-exchange-and-director-dealing/ 2021-05-07T08:09:00+00:00 https://okyopharma.com/tr-1-standard-form-for-notification-of-major-holdings/ 2021-05-12T05:02:00+00:00 https://okyopharma.com/directorate-change-2/ 2021-06-17T14:00:00+00:00 https://okyopharma.com/okyo-pharma-retains-ora-inc-to-perform-regulatory-development-of-ok-101-for-dry-eye-indications/ 2021-06-29T10:49:00+00:00 https://okyopharma.com/final-audited-results-for-the-year-ended-31-march-2021/ 2021-08-02T09:30:00+00:00 https://okyopharma.com/grant-of-options-director-dealings/ 2021-09-01T05:02:00+00:00 https://okyopharma.com/notice-of-annual-general-meeting/ 2021-09-09T05:01:00+00:00 https://okyopharma.com/result-of-annual-general-meeting/ 2021-09-27T10:07:00+00:00 https://okyopharma.com/directorate-change/ 2021-12-01T07:00:00+00:00 https://okyopharma.com/okyo-to-file-ind-in-q3-2022-for-ok-101-to-treat-dry-eye-disease-ded-and-to-go-directly-to-a-phase-2-human-clinical-efficacy-trial-in-ded-patients-with-a-planned-start-date-in-q4-2022-on-an-accelerated/ 2021-12-06T07:00:00+00:00 https://okyopharma.com/first-in-class-drug-candidate-ok-101-displaying-both-anti-inflammatory-and-ocular-pain-reducing-potential-to-treat-dry-eye-disease/ 2021-12-13T07:00:00+00:00 https://okyopharma.com/issuance-of-us-patent-no-11197906-covering-okyo-pharmas-drug-candidate-ok-101-for-use-to-treat-dry-eye-disease/ 2021-12-14T07:00:00+00:00 https://okyopharma.com/okyo-pharma-limited-interim-results-for-the-six-months-to-30-september-2021/ 2022-01-26T07:01:00+00:00 https://okyopharma.com/pdmr-dealing/ 2022-01-27T07:00:00+00:00 https://okyopharma.com/grant-of-options-director-and-pdmr-dealings/ 2022-02-01T07:00:00+00:00 https://okyopharma.com/successful-completion-of-a-pre-ind-meeting-with-the-fda-on-the-development-of-ok-101-to-treat-dry-eye-disease/ 2022-02-15T07:01:00+00:00 https://okyopharma.com/conversion-of-clns-cashless-exercise-of-warrants-and-issue-of-equity/ 2022-02-21T17:00:00+00:00 https://okyopharma.com/okyo-pharma-announces-issuance-of-us-patent-no-11254720-covering-okyos-dry-eye-drug-candidate-ok-101-for-use-to-treat-ocular-neuropathic-pain/ 2022-02-23T07:01:00+00:00 https://okyopharma.com/okyo-publicly-files-a-registration-statement-with-the-sec-for-a-proposed-dual-listing-on-the-nasdaq-capital-market-and-offering-in-the-united-states/ 2022-03-07T07:01:00+00:00 https://okyopharma.com/hello-world-2/ 2022-03-20T17:44:07+00:00 https://okyopharma.com/gabriele-cerrone/ 2022-03-22T21:15:22+00:00 https://okyopharma.com/gary-jacob/ 2022-03-23T20:36:39+00:00 https://okyopharma.com/wp-content/uploads/2022/03/gary-jacob-bwedited-2.jpg https://okyopharma.com/raj-patil-phd/ 2022-03-23T20:43:48+00:00 https://okyopharma.com/wp-content/uploads/2022/04/raj-patil.jpg https://okyopharma.com/keeren-shah/ 2022-03-23T20:54:24+00:00 https://okyopharma.com/wp-content/uploads/2022/05/kereen.jpg https://okyopharma.com/professor-napoleone-ferrara-md/ 2022-03-23T21:03:33+00:00 https://okyopharma.com/willy-simon/ 2022-03-23T21:18:05+00:00 https://okyopharma.com/john-brancaccio/ 2022-03-23T21:20:32+00:00 https://okyopharma.com/wp-content/uploads/2022/06/john.jpg https://okyopharma.com/bernard-denoyer/ 2022-03-23T21:21:50+00:00 https://okyopharma.com/wp-content/uploads/2022/05/bernard.jpg https://okyopharma.com/professor-pedram-hamrah-md-frcs-farvo/ 2022-04-07T17:37:52+00:00 https://okyopharma.com/wp-content/uploads/2022/04/pedram-1.jpg https://okyopharma.com/okyo-pharma-announces-two-presentations-at-the-2022-association-for-research-in-vision-and-ophthalmology-arvo-annual-meeting/ 2022-04-27T06:00:00+00:00 https://okyopharma.com/okyo-pharma-limited-announces-pricing-of-initial-public-offering-of-adss-in-the-u-s-with-director-participation/ 2022-05-17T06:01:00+00:00 https://okyopharma.com/pdmr-dealing_may_18_2022/ 2022-05-18T05:34:00+00:00 https://okyopharma.com/okyo-pharma-limited-announces-closing-of-public-offering-and-nasdaq-listing/ 2022-05-19T05:32:00+00:00 https://okyopharma.com/pdmr-dealing_may_20_2022/ 2022-05-20T06:01:00+00:00 https://okyopharma.com/pdmr-dealing_june_9_2022/ 2022-06-09T06:01:00+00:00 https://okyopharma.com/final-audited-results-for-the-year-ended-31-march-2022/ 2022-08-16T06:00:23+00:00 https://okyopharma.com/notice-of-annual-general-meeting-3/ 2022-08-18T22:00:00+00:00 https://okyopharma.com/okyo-pharma-plans-q4-2022-ind-filing-of-ok-101-to-treat-dry-eye-disease-with-subsequent-phase-2-initiation-alongside-peptide-manufacturing-partner-ambiopharm/ 2022-08-30T06:00:00+00:00 https://okyopharma.com/result-of-annual-general-meeting-3/ 2022-09-07T12:31:13+00:00 https://okyopharma.com/wp-content/uploads/2022/09/Picture1.png https://okyopharma.com/okyo-pharma-limited-interview-to-air-on-bloomberg-u-s-on-the-redchip-money-report/ 2022-09-08T13:30:28+00:00 https://okyopharma.com/okyo-pharma-ltd-announces-participation-in-the-thinkequity-conference/ 2022-10-20T06:01:37+00:00 https://okyopharma.com/okyo-pharma-hosting-key-opinion-leader-event-introducing-ok-101-as-a-potential-treatment-for-dry-eye-disease/ 2022-11-10T11:00:00+00:00 https://okyopharma.com/okyo-pharma-announces-u-s-ind-filing-on-ok-101-for-the-treatment-of-dry-eye-disease/ 2022-11-21T07:02:47+00:00 https://okyopharma.com/grant-of-options-pdmr-dealing/ 2022-11-24T07:03:52+00:00 https://okyopharma.com/change-of-auditor/ 2022-12-01T07:03:35+00:00 https://okyopharma.com/okyo-publicly-files-a-registration-statement-with-the-sec/ 2022-12-06T07:04:47+00:00 https://okyopharma.com/okyo-to-participate-at-biotech-showcase/ 2022-12-21T07:00:00+00:00 https://okyopharma.com/okyo-pharma-announces-u-s-fda-clearance-of-ind-application-for-ok-101-for-the-treatment-of-dry-eye-disease/ 2022-12-22T07:01:51+00:00 https://okyopharma.com/interim-results-for-the-six-months-ending-30-september-2022/ 2022-12-30T07:01:00+00:00 https://okyopharma.com/allotment-of-shares-and-total-voting-rights/ 2023-02-14T08:37:38+00:00 https://okyopharma.com/okyo-pharma-to-present-at-the-second-annual-gpcrs-targeted-drug-discovery-summit-in-boston-ma-on-february-21-23-2023/ 2023-02-21T07:01:00+00:00 https://okyopharma.com/jay-s-pepose-md-phd-farvo/ 2023-02-23T07:00:00+00:00 https://okyopharma.com/wp-content/uploads/2023/02/JSP-headshot2.jpg https://okyopharma.com/world-renowned-ophthalmologist-with-expertise-in-the-medical-and-surgical-treatment-of-ocular-surface-diseases-joins-advisory-board-of-okyo-pharma/ 2023-02-23T07:01:00+00:00 https://okyopharma.com/okyo-pharma-announces-custom-clearance-of-gmp-packaged-ok-101-drug-to-be-used-in-phase-2-clinical-trial-for-treating-dry-eye-disease/ 2023-02-28T07:01:00+00:00 https://okyopharma.com/ceo-of-okyo-pharma-inc-dr-gary-jacob-interviewed-by-leading-publishersmallcapsdaily/ 2023-03-13T15:25:25+00:00 https://okyopharma.com/okyo-pharma-limited-announces-u-s-5-74-million-global-private-placement-and-investment-by-directors-and-members-of-senior-management/ 2023-03-14T07:01:00+00:00 https://okyopharma.com/wp-content/uploads/2022/04/okyo-pharma-logo.png https://okyopharma.com/okyo-pharma-announces-that-the-board-of-directors-of-the-company-acting-on-a-recommendation-of-the-remuneration-committee-has-awarded-options-to-directors-and-persons-discharging-managerial-responsib/ 2023-03-15T07:01:00+00:00 https://okyopharma.com/closing-of-global-private-placement/ 2023-03-16T07:00:00+00:00 https://okyopharma.com/okyo-pharma-announces-phase-2-trial-of-ok-101-drug-to-treat-dry-eye-disease-is-now-listed-on-the-clinicaltrials-gov-public-website/ 2023-03-16T07:01:00+00:00 https://okyopharma.com/pdmr-dealing-2/ 2023-03-24T07:01:00+00:00 https://okyopharma.com/okyo-pharma-today-announces-director-acquires-shares/ 2023-03-29T06:01:00+00:00 https://okyopharma.com/okyo-pharma-today-announces-director-acquires-shares-2/ 2023-03-30T06:02:00+00:00 https://okyopharma.com/notice-of-intention-to-delist-from-the-london-stock-exchange/ 2023-04-04T06:01:00+00:00 https://okyopharma.com/notice-of-general-meeting-and-publication-of-circular/ 2023-04-05T06:01:00+00:00 https://okyopharma.com/okyo-pharma-announces-activation-of-first-clinical-trial-site-in-the-u-s-for-the-phase-2-trial-evaluating-ok-101-for-the-treatment-of-dry-eye-disease/ 2023-04-25T06:01:00+00:00 https://okyopharma.com/okyo-pharma-announces-first-patient-first-visit-for-phase-2-trial-evaluating-efficacy-and-safety-of-ok-101-in-patients-with-dry-eye-disease/ 2023-05-02T06:00:00+00:00 https://okyopharma.com/okyo-pharma-announces-presentations-at-the-american-society-of-cataract-and-refractive-surgery-ascrs-2023-in-san-diego-ca-may-5-8-2023/ 2023-05-03T06:00:00+00:00 https://okyopharma.com/result-of-general-meeting/ 2023-05-03T12:10:42+00:00 https://okyopharma.com/change-of-delisting-date-to-22-may-2023/ 2023-05-11T06:01:00+00:00 https://okyopharma.com/okyo-pharma-now-participating-on-the-webull-corporate-communications-service-platform/ 2023-05-11T11:00:00+00:00 https://okyopharma.com/change-of-record-time-and-last-day-of-dealings/ 2023-05-15T06:00:00+00:00 https://okyopharma.com/ads-program-collapse-commencement-of-trading-of-new-ordinary-shares-on-the-nasdaq-capital-market/ 2023-05-19T07:01:00+00:00 https://okyopharma.com/london-stock-exchange-delisting/ 2023-05-22T07:15:00+00:00 https://okyopharma.com/okyo-pharma-announces-randomized-segment-now-underway-in-phase-2-clinical-trial-of-topical-ocular-ok-101-for-dry-eye-disease/ 2023-06-06T13:30:00+00:00 https://okyopharma.com/okyo-pharma-announces-appointment-of-william-a-clementi-as-chief-operating-officer/ 2023-07-27T15:30:00+00:00 https://okyopharma.com/okyo-pharma-plans-to-initiate-phase-2-trial-of-ok-101-in-neuropathic-corneal-pain-ncp-following-announcement-of-clinical-trial-agreement-with-tufts-medical-center/ 2023-07-28T11:01:00+00:00 https://okyopharma.com/wp-content/uploads/2022/04/okyo-pharma-logo.png https://okyopharma.com/okyo-pharma-limited-receives-nasdaq-deficiency-notice/ 2023-07-28T21:05:00+00:00 https://okyopharma.com/okyo-pharma-announces-proposed-public-offering-of-ordinary-shares/ 2023-07-28T21:25:00+00:00 https://okyopharma.com/okyo-pharma-limited-announces-withdrawal-of-public-offering/ 2023-07-31T08:12:08+00:00 https://okyopharma.com/okyo-pharma-limited-reports-annual-results-for-the-twelve-months-ended-march-31-2023/ 2023-08-15T13:00:00+00:00 https://okyopharma.com/okyo-pharma-limited-regains-compliance-with-nasdaq-listing-minimum-market-value-rule/ 2023-08-29T11:00:00+00:00 https://okyopharma.com/okyo-pharma-achieves-90-enrollmentin-240-patient-phase-2-clinical-trial-of-ok-101-to-treat-dry-eye-disease-ded/ 2023-08-30T11:00:00+00:00 https://okyopharma.com/okyo-pharma-completes-enrollment-in-phase-2-clinical-trial-of-ok-101-to-treat-dry-eye-disease/ 2023-09-08T11:00:00+00:00 https://okyopharma.com/okyo-pharma-announces-public-offering-of-ordinary-shares/ 2023-09-13T20:05:00+00:00 https://okyopharma.com/okyo-pharma-limited-announces-withdrawal-of-public-offering-2/ 2023-09-14T12:55:22+00:00 https://okyopharma.com/okyo-pharma-announces-pricing-of-4-0-million-registered-direct-offering-of-ordinary-shares/ 2023-09-15T07:30:12+00:00 https://okyopharma.com/okyo-pharma-announces-closing-of-4-0-million-registered-direct-offering-of-ordinary-shares/ 2023-09-15T11:03:16+00:00 https://okyopharma.com/okyo-pharma-announces-positive-safety-data-profile-for-the-ongoing-ok-101-phase-2-clinical-trial-to-treat-dry-eye-disease-ded/ 2023-10-05T11:00:00+00:00 https://okyopharma.com/okyo-pharma-announces-filing-of-an-investigational-new-drug-ind-application-for-ok-101-to-treat-neuropathic-corneal-pain-ncp/ 2023-10-09T11:00:00+00:00 https://okyopharma.com/okyo-pharma-announces-5-84-million-cash-raise-and-payables-reduction/ 2023-10-31T11:00:00+00:00 https://okyopharma.com/okyo-pharma-announces-last-patient-enrolled-in-ok-101-phase-2-clinical-trial-to-treat-dry-eye-disease-has-completed-final-protocol-visit/ 2023-12-04T12:00:00+00:00 https://okyopharma.com/okyo-pharma-to-present-at-the-biotech-showcase-conference-in-san-francisco-january-8-10-2024/ 2024-01-05T14:30:00+00:00 https://okyopharma.com/okyo-pharma-announces-ok-101-successfully-achieved-statistical-significance-for-both-sign-and-symptom-endpoints-in-its-first-in-human-phase-2-trial-of-ok-101-in-patients-with-dry-eye-disease/ 2024-01-08T12:00:00+00:00 https://okyopharma.com/okyo-pharma-announces-distinguished-ophthalmologists-with-expertise-in-the-medical-and-surgical-treatment-of-ocular-surface-diseases-join-its-scientific-advisory-board/ 2024-01-31T12:00:00+00:00 https://okyopharma.com/wp-content/uploads/2023/07/cropped-favi-1.png https://okyopharma.com/okyo-pharma-receives-fda-approval-of-ind-for-ok-101-in-neuropathic-corneal-pain/ 2024-03-19T12:47:28+00:00 https://okyopharma.com/wp-content/uploads/2023/07/cropped-favi-1.png https://okyopharma.com/okyo-pharma-to-release-new-and-comprehensive-data-from-phase-2-dry-eye-disease-trial-and-host-key-opinion-leader-event/ 2024-03-20T11:44:12+00:00 https://okyopharma.com/wp-content/uploads/2023/07/cropped-favi-1.png https://okyopharma.com/okyo-pharma-to-host-key-opinion-leader-event-to-discuss-new-and-comprehensive-data-from-phase-2-dry-eye-disease-trial/ 2024-03-21T11:00:00+00:00 https://okyopharma.com/wp-content/uploads/2023/07/cropped-favi-1.png https://okyopharma.com/okyo-pharma-announces-ok-101-successfully-achieved-statistical-significance-for-multiple-signs-and-symptoms-of-dry-eye-disease-including-ocular-pain-relief-in-its-first-in-human-phase-2-trial-of-ok-10/ 2024-03-22T11:00:00+00:00 https://okyopharma.com/wp-content/uploads/2023/07/cropped-favi-1.png https://okyopharma.com/okyo-pharma-announces-upcoming-presentation-of-ok-101-phase-2-data-for-dry-eye-disease-at-eyecelerator-2024-a-partner-meeting-of-the-american-society-for-cataract-and-refractive-surgery/ 2024-04-02T11:00:00+00:00 https://okyopharma.com/wp-content/uploads/2024/04/Eyecelerator.jpg https://okyopharma.com/okyo-pharma-to-reschedule-key-opinion-leader-event-in-dry-eye-disease-to-may-2024/ 2024-04-08T23:01:00+00:00 https://okyopharma.com/wp-content/uploads/2023/07/cropped-favi-1.png https://okyopharma.com/okyo-pharma-announces-upcoming-presentation-of-ok-101-phase-2-data-for-dry-eye-disease-at-the-dry-horizons-symposium-a-partner-meeting-of-the-association-for-research-in-vision-and-ophthalmology-arv/ 2024-04-30T11:00:00+00:00 https://okyopharma.com/wp-content/uploads/2023/07/cropped-favi-1.png https://okyopharma.com/okyo-pharma-announces-participation-in-may-2024-investor-conferences/ 2024-05-08T11:00:00+00:00 https://okyopharma.com/wp-content/uploads/2023/07/cropped-favi-1.png https://okyopharma.com/okyo-pharma-announces-promising-categorical-data-from-ok-101-phase-2-trial-in-dry-eye-disease/ 2024-07-10T11:00:00+00:00 https://okyopharma.com/wp-content/uploads/2024/07/DED-PR-Image.png https://okyopharma.com/wp-content/uploads/2024/07/DED-PR-Image.png https://okyopharma.com/okyo-pharma-receives-1-9-million-in-non-dilutive-funding-to-accelerate-development-of-urcosimod-for-neuropathic-corneal-pain/ 2025-07-25T09:45:36+00:00 https://okyopharma.com/wp-content/uploads/2023/07/favi-1.png https://okyopharma.com/okyo-pharma-unveils-strong-phase-2-clinical-trial-results-for-urcosimod-to-treat-neuropathic-corneal-pain/ 2025-07-25T10:10:38+00:00 https://okyopharma.com/wp-content/uploads/2025/06/Okyo-RGB-stacked.jpg https://okyopharma.com/okyo-pharma-to-present-at-the-bio-international-convention/ 2025-07-25T10:11:06+00:00 https://okyopharma.com/wp-content/uploads/2025/06/BIO2025-Social-Posts-v1-25.png https://okyopharma.com/okyo-pharma-to-present-at-the-gpcrs-targeted-drug-discovery-summit/ 2025-07-25T10:11:31+00:00 https://okyopharma.com/wp-content/uploads/2025/05/GPCRs-SEO-Image.png https://okyopharma.com/fda-grants-okyo-pharma-fast-track-designation-to-urcosimod-for-neuropathic-corneal-pain/ 2025-07-25T10:12:00+00:00 https://okyopharma.com/wp-content/uploads/2025/05/FDA-Large.jpg https://okyopharma.com/okyo-pharma-announces-plans-to-accelerate-the-clinical-development-of-urcosimod-to-treat-neuropathic-corneal-pain/ 2025-07-25T10:12:27+00:00 https://okyopharma.com/wp-content/uploads/2023/07/cropped-favi-1.png https://okyopharma.com/okyo-pharma-announces-positive-data-in-long-term-stability-of-urcosimod/ 2025-07-25T10:12:57+00:00 https://okyopharma.com/wp-content/uploads/2023/07/favi-1.png https://okyopharma.com/okyo-pharma-files-for-fast-track-designation-with-fda-for-urcosimod-to-treat-neuropathic-corneal-pain/ 2025-07-25T10:13:26+00:00 https://okyopharma.com/wp-content/uploads/2023/07/cropped-favi-1.png https://okyopharma.com/okyo-pharma-announces-ok-101-officially-assigned-usan-urcosimod/ 2025-07-25T10:13:52+00:00 https://okyopharma.com/wp-content/uploads/2023/07/favi-1.png https://okyopharma.com/okyo-pharma-announces-chairman-and-ceo-acquire-shares/ 2025-07-25T10:14:18+00:00 https://okyopharma.com/wp-content/uploads/2023/07/favi-1.png https://okyopharma.com/okyo-pharma-to-complete-enrollment-of-neuropathic-corneal-pain-trial-by-end-of-second-quarter/ 2025-07-25T10:14:46+00:00 https://okyopharma.com/wp-content/uploads/2023/07/cropped-favi-1.png https://okyopharma.com/okyo-pharma-receives-1-4-million-in-non-dilutive-funding/ 2025-07-25T10:15:33+00:00 https://okyopharma.com/wp-content/uploads/2023/07/cropped-favi-1.png https://okyopharma.com/okyo-pharma-to-participate-at-the-4th-annual-btig-ophthalmology-conference/ 2025-07-25T10:16:10+00:00 https://okyopharma.com/wp-content/uploads/2024/11/btig.jpg https://okyopharma.com/okyo-pharma-to-present-at-international-tear-film-and-ocular-surface-society-conference/ 2025-07-25T10:17:15+00:00 https://okyopharma.com/wp-content/uploads/2024/10/TFOS-save-the-date.jpg https://okyopharma.com/okyo-pharma-announces-first-patient-dosed-in-the-first-clinical-trial-to-treat-neuropathic-corneal-pain/ 2025-07-25T10:18:09+00:00 https://okyopharma.com/wp-content/uploads/2023/06/occular-pain-1024x539-1.jpeg https://okyopharma.com/okyo-pharma-announces-start-of-phase-2-clinical-trial-to-treat-patients-with-neuropathic-corneal-pain/ 2025-07-25T10:18:37+00:00 https://okyopharma.com/wp-content/uploads/2023/07/cropped-favi-1.png https://okyopharma.com/okyo-pharma-announces-chairman-acquires-shares-4/ 2025-07-25T10:19:03+00:00 https://okyopharma.com/wp-content/uploads/2023/07/cropped-favi-1.png https://okyopharma.com/okyo-pharma-announces-chairman-acquires-shares-3/ 2025-07-25T10:20:07+00:00 https://okyopharma.com/wp-content/uploads/2023/07/cropped-favi-1.png https://okyopharma.com/okyo-pharma-granted-u-s-patent-covering-ok-101s-potential-for-treating-symptoms-of-dry-eye-disease/ 2025-07-25T10:20:42+00:00 https://okyopharma.com/wp-content/uploads/2024/08/Patented-Logo.jpg https://okyopharma.com/okyo-pharma-ceo-interview-to-air-on-bloomberg-tv/ 2025-07-25T10:21:28+00:00 https://okyopharma.com/wp-content/uploads/2024/08/bloomberg_logo.jpg https://okyopharma.com/okyo-pharma-announces-chairman-acquires-shares-2/ 2025-07-25T10:22:47+00:00 https://okyopharma.com/wp-content/uploads/2023/06/okyo-pharma-logo.png https://okyopharma.com/okyo-pharma-announces-chairman-acquires-shares/ 2025-07-25T10:23:22+00:00 https://okyopharma.com/wp-content/uploads/2023/07/cropped-favi-1.png https://okyopharma.com/okyo-pharma-participates-in-h-c-wainwright-4th-annual-ophthalmology-virtual-conference/ 2025-07-25T10:24:19+00:00 https://okyopharma.com/wp-content/uploads/2024/08/HCW_neg_logo1.png https://okyopharma.com/okyo-pharma-granted-european-patent-covering-ok-101-chemerin-analogs-and-their-method-of-use/ 2025-07-25T10:24:56+00:00 https://okyopharma.com/wp-content/uploads/2023/07/favi-1.png https://okyopharma.com/okyo-pharma-to-initiate-neuropathic-corneal-pain-trial-for-ok-101/ 2025-07-25T10:25:48+00:00 https://okyopharma.com/wp-content/uploads/2023/07/favi-1.png https://okyopharma.com/okyo-pharma-announces-registration-pathway-with-100-patient-multi-center-clinical-trial-of-urcosimod-in-neuropathic-corneal-pain/ 2025-09-22T12:30:00+00:00 https://okyopharma.com/wp-content/uploads/2025/06/Okyo-RGB-stacked.jpg https://okyopharma.com/okyo-pharma-announces-chairman-and-founder-acquires-shares/ 2025-10-16T12:30:00+00:00 https://okyopharma.com/wp-content/uploads/2025/06/Okyo-RGB-stacked.jpg https://okyopharma.com/okyo-pharma-to-present-at-bio-europe-2025-in-vienna/ 2025-10-30T11:33:03+00:00 https://okyopharma.com/wp-content/uploads/2025/10/Bio-Europe-We-presenting-at.jpg https://okyopharma.com/okyo-pharma-to-present-at-ois-xv-in-san-diego/ 2025-11-18T13:30:00+00:00 https://okyopharma.com/wp-content/uploads/2025/11/Okyo-Pharma-GIF.gif https://okyopharma.com/okyo-pharma-announces-chairman-and-founder-acquires-shares-2/ 2025-11-21T13:30:00+00:00 https://okyopharma.com/wp-content/uploads/2025/06/Okyo-RGB-stacked.jpg https://okyopharma.com/okyo-pharma-announces-chairman-and-founder-acquires-shares-3/ 2025-12-03T12:00:00+00:00 https://okyopharma.com/wp-content/uploads/2025/06/Okyo-RGB-stacked.jpg https://okyopharma.com/okyo-pharma-announces-new-data-showing-favorable-corneal-nerve-outcomes-in-phase-2-study-for-neuropathic-corneal-pain/ 2025-12-11T13:30:00+00:00 https://okyopharma.com/wp-content/uploads/2025/06/Okyo-RGB-stacked.jpg https://okyopharma.com/okyo-pharma-announces-chairman-and-founder-acquires-shares-4/ 2025-12-15T13:30:00+00:00 https://okyopharma.com/wp-content/uploads/2025/06/Okyo-RGB-stacked.jpg https://okyopharma.com/okyo-pharma-to-ring-the-opening-bell-at-nasdaq/ 2025-12-19T14:55:07+00:00 https://okyopharma.com/wp-content/uploads/2025/12/OKYO-MO_121925_tower-shot_0.jpg https://okyopharma.com/okyo-pharma-appoints-industry-veteran-robert-j-dempsey-as-chief-executive-officer/ 2026-01-05T12:00:00+00:00 https://okyopharma.com/wp-content/uploads/2026/01/Bob-Dempsey.jpg https://okyopharma.com/fda-approves-compassionate-use-of-urcosimod-0-05-for-the-treatment-of-neuropathic-corneal-pain/ 2026-01-23T14:53:03+00:00 https://okyopharma.com/wp-content/uploads/2023/06/pedram-1.jpeg https://okyopharma.com/okyo-pharma-announces-successful-type-c-meeting-with-the-fda/ 2026-01-29T12:18:25+00:00 https://okyopharma.com/wp-content/uploads/2026/01/OKYO-FDA-Type-C-Meeting.jpg https://okyopharma.com/okyo-pharma-announces-acceptance-of-urcosimod-phase-2-study-results-for-presentation-at-prestigious-ascrs-annual-meeting/ 2026-01-30T16:30:00+00:00 https://okyopharma.com/wp-content/uploads/2026/01/OKYO-Pharma-Urcosimod-ASCRS-Presentation-Accepted-1.png https://okyopharma.com/okyo-pharma-strengthens-world-class-leadership-team-with-appointment-of-flavio-mantelli-md-phd-as-chief-medical-officer/ 2026-02-10T13:00:00+00:00 https://okyopharma.com/wp-content/uploads/2026/02/LI-Flavio-CMO.jpg https://okyopharma.com/okyo-pharma-announces-transition-of-at-the-market-equity-offering-facility-to-leerink-partners/ 2026-02-11T15:11:12+00:00 https://okyopharma.com/wp-content/uploads/2026/02/Handshake.jpg https://okyopharma.com/okyo-pharma-announces-public-offering-of-ordinary-shares-2/ 2026-02-12T21:01:00+00:00 https://okyopharma.com/wp-content/uploads/2025/06/Okyo-RGB-stacked.jpg https://okyopharma.com/okyo-pharma-announces-pricing-of-20-million-public-offering-of-ordinary-shares/ 2026-02-13T03:30:00+00:00 https://okyopharma.com/wp-content/uploads/2025/06/Okyo-RGB-stacked.jpg https://okyopharma.com/okyo-pharma-announces-abstract-acceptance-for-presentation-at-arvo-2026-a-premier-global-ophthalmology-congress/ 2026-02-23T16:00:00+00:00 https://okyopharma.com/wp-content/uploads/2026/02/OKYO-Pharma-to-Present-at-Preeminent-ARVO-2026-Conference.png https://okyopharma.com/okyo-pharma-reports-new-phase-2-data-demonstrating-meaningful-improvements-in-patient-reported-quality-of-life-outcomes-with-urcosimod-in-neuropathic-corneal-pain/ 2026-03-18T11:00:00+00:00 https://okyopharma.com/wp-content/uploads/2025/06/Okyo-RGB-stacked.jpg https://okyopharma.com/okyo-pharma-announces-chief-development-officer-and-director-acquires-shares/ 2026-03-19T11:00:00+00:00 https://okyopharma.com/wp-content/uploads/2025/06/Okyo-RGB-stacked.jpg https://okyopharma.com/okyo-pharma-announces-director-acquires-shares/ 2026-03-19T14:00:00+00:00 https://okyopharma.com/wp-content/uploads/2025/06/Okyo-RGB-stacked.jpg https://okyopharma.com/okyo-pharma-announces-chairman-and-founder-acquires-shares-5/ 2026-03-19T16:00:00+00:00 https://okyopharma.com/wp-content/uploads/2025/06/Okyo-RGB-stacked.jpg https://okyopharma.com/okyo-pharma-announces-scientific-advisory-board-meeting-and-urcosimod-data-presentation-during-ascrs-annual-meeting/ 2026-04-07T11:00:00+00:00 https://okyopharma.com/wp-content/uploads/2026/04/OKYO-ASCRS-SAB.jpg https://okyopharma.com/okyo-ceo-and-cso-to-present-and-leadership-team-to-participate-at-upcoming-scientific-conferences-in-may/ 2026-04-29T14:51:25+00:00 https://okyopharma.com/wp-content/uploads/2026/04/OKYO-ARVO-2026.png https://okyopharma.com/okyo-expands-scientific-advisory-board-with-the-appointment-of-international-expert-marta-sacchetti-md-phd/ 2026-05-19T11:00:00+00:00 https://okyopharma.com/wp-content/uploads/2026/05/OKYO-Marta-SAB.jpg